New drug cocktail aims to outsmart advanced cancers

NCT ID NCT04693468

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other drugs target different growth signals. The study involves about 111 participants and focuses on finding the best doses and understanding side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Talazoparib combined with palbociclib, axitinib, or crizotinib
What this could lead to
If successful, this could point toward new combination treatments that help control advanced solid tumors by blocking cancer cell repair and growth.
What could go wrong
This is an early phase 1 trial with a small number of participants, so it may not lead to a proven treatment. Side effects from the drug combinations are possible and will be closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.